Press releases

Date	Title	View
November 20, 2024	Caribou Biosciences to Participate in Upcoming Investor Conferences	PDF Version
November 6, 2024	Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update	PDF Version
September 25, 2024	Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024	PDF Version
September 3, 2024	Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML	PDF Version
August 26, 2024	Caribou Biosciences to Participate in Upcoming Investor Conferences	PDF Version
August 12, 2024	Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer	PDF Version
August 6, 2024	Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update	PDF Version
July 9, 2024	Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board	PDF Version
June 2, 2024	Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	PDF Version
May 30, 2024	Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences	PDF Version